Reading OPK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OPK free→Reading OPK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OPK free→
NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been steady. Risk is moderate, and the sector backdrop is a headwind. Peer multiples imply a price about 82% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern suggests weakness in recent financials or fragile earnings quality. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $1.39. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $1.40 OPK trades at 2× p/s, below its 4× p/s peer median. Our $6.84 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 80% below a flat-multiple fair value, below our forecast of about -15%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.00x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.11. 0 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 57% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$163.
How much price usually moves either way.
On a bad day, this stock has moved -$336.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,038.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If healthcare sector revenue growth speeds up, it may help OPKO's performance. This could signal a better environment for OPKO.
Confirms:Healthcare sector revenue growth exceeds 10% year over year.
Disproves:Healthcare sector revenue growth remains below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for OPK yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On April 28, 2026, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended March 31, 2026. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the first quarter ended March 31, 2026, as well as provide financial guidance. A copy of the press releas…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2024-Q3, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Life Sciences Tools & Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
OPK OPKO Health, Inc. | — | inexpensive | moderate |
TMO Thermo Fisher Scientific | Above typical Show detailsSector percentile: 95 of 100 | fair | moderate |
DHR Danaher Corporation | Above typical Show detailsSector percentile: 97 of 100 | fair | moderate |
A Agilent Technologies | Above typical Show detailsSector percentile: 94 of 100 | full | moderate |
WAT Waters Corporation | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Management aims to achieve total revenue guidance of $530M-$560M for the fiscal year 2026.
Management is focused on improving operating income, which has been negative in recent quarters.
Management aims to increase gross profit, which has fluctuated over recent quarters.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 18, 2026, the Board of Directors of OPKO Health, Inc. (the “Company”), appointed Subbarao V. Uppaluri, Ph.D. as a new director with immediate effect to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor shall be duly elected or appointed or his earlier death or resignation. Dr. Uppaluri is expected to be…
Results of Operations and Financial Condition. On February 26, 2026, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter and year ended December 31, 2025. The press release also contains information on how to access the conference call the Company is hosting to discuss its financial and operating results for the fourth quarter and year ended December 31, 2025, as well as provide business updates and financial guidance. A copy…
Results of Operations and Financial Condition. On October 29, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended September 30, 2025. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the third quarter ended September 30, 2025, as well as provide financial guidance. A copy of the pr…
Results of Operations and Financial Condition. On July 31, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended June 30, 2025. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the second quarter ended June 30, 2025, as well as provide financial guidance. A copy of the press release…